# Frontage Plans HKEX Privatization With Charles River, Tigermed and Chairman Song Li Splitting Assets

> Frontage Holdings proposed a privatization from the HKEX and a restructuring that would divide its business among Charles River Laboratories.

- Published: 2026-11-16T18:39:13+00:00
- Section: Mergers & Acquisitions
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-16/frontage-privatization-asset-restructuring
- Source: [TradingView](https://www.tradingview.com/news/prnewswire:2d5f4f3c2348b:0-frontage-announces-proposed-privatization-and-asset-restructuring-to-unlock-shareholder-value-and-fuel-strategic-growth/)

## Key takeaways

- Frontage Holdings proposed a privatization from the HKEX followed by an asset restructuring involving Charles River Laboratories, Tigermed and Dr. Song Li.
- Charles River Laboratories is expected to own and operate Frontage's Exton, Pennsylvania bioanalysis and DMPK business after the restructuring.
- The transaction remains subject to shareholder and regulatory approvals and customary closing conditions.

Frontage Holdings Corporation announced a proposal by an investor consortium to take the company private from the HKEX and then restructure its assets, with the business expected to be divided among Charles River Laboratories, Tigermed and Dr. Song Li, Frontage's Chairman. The proposal was announced in a [TradingView](https://www.tradingview.com/news/prnewswire:2d5f4f3c2348b:0-frontage-announces-proposed-privatization-and-asset-restructuring-to-unlock-shareholder-value-and-fuel-strategic-growth/) report on November 16, 2026.

## How the Frontage Asset Split Would Work

Under the restructuring, Frontage's Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business is expected to be owned and operated by [Charles River Laboratories](https://akta.pro/company-profiles/0000c1w/charles-river-laboratories-international). Frontage's business in the People's Republic of China and the business currently owned and operated by Acme Bioscience, Inc. and/or its subsidiaries are expected to be owned and operated by [Tigermed](https://akta.pro/company-profiles/0006z88/tigermed). Frontage's remaining business outside the PRC, including bioanalysis and DMPK outside of Exton, Pennsylvania, is expected to be owned and operated by Dr. Song Li.

"The Transaction aims to unlock shareholder value and position Frontage for future long-term growth," Dr. Wentao Zhang and Dr. Zhongping Lin, Executive Directors and Co-CEOs of Frontage, said in the announcement. "The proposed privatization will allow management to redeploy resources directly into core operations, while the subsequent restructuring of Frontage's business will empower local business units to navigate evolving regulatory frameworks, market conditions and client dynamics with greater focus and agility."

The transaction remains subject to shareholder and regulatory approvals, as well as customary closing conditions. Frontage said it will continue its business operations in the ordinary course until the transaction closes, and that the same team will support clients on ongoing projects, studies and contracts with the same quality and timelines. Wilson Sonsini Goodrich & Rosati is serving as legal advisor to Frontage.

## Frontage's Recent Expansion Moves

According to akta.pro [company records](https://akta.pro/company-data), Frontage completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. in March 2026. The Chinese central lab supported over 1,500 clinical trials and contributed to 50 drug approvals, establishing a major Asia-Pacific central laboratory footprint. The same records list 28 sites across North America, Asia-Pacific and Europe and approximately 2,200 employees worldwide.

## Earlier Steps Toward the Frontage Deal

In November 2026, Tigermed proposed to privatize its subsidiary Frontage Holdings and divest Frontage's overseas laboratory services business to Charles River Laboratories and Dr. Song Li, retaining China operations, according to PR Newswire. In September 2026, [Frontage Laboratories](https://akta.pro/company-profiles/0002ryh/frontage-laboratories) was described as a US-based contract research organization founded in 2001 that moved to Pennsylvania in 2004 and operates 26 facilities across multiple countries, according to a LinkedIn post cited in the timeline. In June 2026, Frontage appointed Dr. Chandra Prakash, Ph.D. as Senior Advisor, Clinical Services, bringing four decades of expertise in drug metabolism, pharmacokinetics and clinical pharmacology, according to PR Newswire.

## What Comes Next for Frontage Shareholders

Further details on the transaction, including the expected schedule for shareholder meetings, will be set out in a shareholder document to be dispatched to Frontage shareholders in due course, the company said.

## Companies in this story

- [Frontage Laboratories company profile](https://akta.pro/company-profiles/0002ryh/frontage-laboratories) · website: http://frontagelab.com
- [Charles River Laboratories International company profile](https://akta.pro/company-profiles/0000c1w/charles-river-laboratories-international) · website: http://www.criver.com
- [Tigermed company profile](https://akta.pro/company-profiles/0006z88/tigermed) · website: https://tigermedgrp.com

---
News for Agent · https://newsforagent.com/llms.txt
